Short answer
Larimar Therapeutics, Inc. (LRMR) filed its Q2 2026 10-Q quarterly report on Aug 4, 2026 for the quarter ended Jun 30, 2026.
Q2 2026 key financials · XBRL
- Net income
- −$33M
- −25.2% YoY · −10.7% QoQ
Source: XBRL data from the Larimar Therapeutics, Inc. (LRMR) Q2 2026 10-Q on SEC EDGAR. USD.
Larimar Therapeutics, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Newly added BLA risk triggered by June 2026 submission; FDA may refuse filing or deny accelerated approval
- Most material regulatory update: fill-finish manufacturer received an FDA Form 483, requiring remediation before review
- Safety-database adequacy remains subject to FDA review at BLA submission
- Third-party site inspections could delay BLA submission or approval
- Manufacturing continuity risk from dependence on third-party suppliers and qualification of an additional fill-finish source
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Larimar Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.